Hydrophilic/lipophilic polymeric matrix dosage formulation

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 9/24 (2006.01) A61K 9/20 (2006.01) A61K 31/4045 (2006.01) A61K 31/506 (2006.01) A61K 31/5377 (2006.01) A61P 25/16 (2006.01)

Patent

CA 2405508

An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.

L'invention concerne une forme posologique orale constituée d'un comprimé pharmaceutique comprenant une ou plusieurs couches, l'une desdites couches renfermant une substance biologiquement active. La formulation dudit comprimé comprend différents pourcentages de matières polymères hydrophiles et lipophiles et de substances adjuvantes. Les comprimés selon la présente invention présentent une vitesse de libération indépendante de la quantité de substance active contenue dans le comprimé.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Hydrophilic/lipophilic polymeric matrix dosage formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydrophilic/lipophilic polymeric matrix dosage formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrophilic/lipophilic polymeric matrix dosage formulation will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1489487

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.